Inhibikase Therapeutics (IKT) investor relations material

Disease overview and unmet need

• Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening disease with a 30% five-year mortality rate despite aggressive treatment.

• PAH affects approximately 50,000 people in the US and 26,000 in the EU5, with high economic burden and reduced quality of life.

• Current therapies are mainly vasodilators, with only one approved antiproliferative, highlighting a significant unmet medical need.

Market opportunity

• The PAH market is valued at $8.3 billion in 2025 and is expected to grow rapidly, potentially reaching $14 billion by 2034.

• Antiproliferatives, especially those with disease-modifying properties and patient-friendly administration, are expected to become a cornerstone of PAH therapy.

• US sales of sotatercept, a leading antiproliferative, are projected to reach $2–2.5 billion in 2026.

IKT-001 product profile and mechanism

• IKT-001 is a novel oral prodrug of imatinib designed to retain efficacy while improving gastrointestinal tolerability.

• Demonstrates class-leading efficacy with a 45-meter placebo-adjusted improvement in 6-minute walk distance (6MWD) in prior studies.

• Mechanistically, IKT-001 targets aberrant cell proliferation in PAH by inhibiting PDGFR and c-Kit, addressing the underlying disease process.

• Preclinical models show IKT-001 reverses pulmonary vascular remodeling and improves survival, mirroring imatinib’s effects.